Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 7:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 244 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Eicosapentaenoic Acid Clear all
Not listed Phase 2 Interventional

An Open-Label Study of Vascazen in Cardiac Rehab Patients With Deficient Blood Omega-3 Fatty Acid Levels

NCT02052986
View directory record Official record
Conditions
Dyslipidemia
Interventions
VASCAZEN
Other
Lead sponsor
New York Hospital Queens
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Fresh Meadows, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Oct 4, 2026, 7:18 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Investigating the Effects of Nutrition on the Maturation of Brain Networks Associated With Memory in Infants

NCT02457078
View directory record Official record
Conditions
Healthy
Interventions
Postnatal Dietary Supplement, Control Supplement
Dietary Supplement
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 4, 2026, 7:18 AM EDT
Completed Phase 1 Interventional Results available

DHA For The Treatment of Pediatric Concussion Related to Sports Injury

NCT01903525
View directory record Official record
Conditions
Concussion, Mild Traumatic Brain Injury
Interventions
Docosahexaenoic acid (DHA), Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
14 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Plano, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 4, 2026, 7:18 AM EDT
Terminated Phase 4 Interventional

Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels

NCT00578578
View directory record Official record
Conditions
Coronary Artery Disease, Inflammatory Response, Atherosclerosis
Interventions
eicosapentaenoic acid (EPA),
Dietary Supplement
Lead sponsor
The Cleveland Clinic
Other
Eligibility
19 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Willoughby Hills, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 21, 2007 · Synced Oct 4, 2026, 7:18 AM EDT
Completed Phase 2 Interventional Results available

Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder

NCT01694667
View directory record Official record
Conditions
Autism Spectrum Disorders, Hyperactivity
Interventions
Omega-3 Fatty Acids, Placebo
Drug · Other
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
5 Years to 8 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Multiple Locations, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Oct 4, 2026, 7:18 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Effects of Vitamin D and Omega-3 Supplementation on Telomeres in VITAL

NCT04386577
View directory record Official record
Conditions
Aging
Interventions
Vitamin D3 (cholecalciferol), fish oil
Dietary Supplement · Drug
Lead sponsor
Augusta University
Other
Eligibility
50 Years and older
Enrollment
1,054 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Oct 4, 2026, 7:18 AM EDT
Completed Phase 3 Interventional Results available

Effects of Vitamin D and Fish Oil on the Kidney in Hypertensives

NCT02757872
View directory record Official record
Conditions
Hypertension, Kidney Diseases
Interventions
Vitamin D3, Omega-3 Fatty acids, Vitamin D3 placebo, Fish oil placebo
Dietary Supplement · Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
50 Years to 99 Years
Enrollment
2,232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 31, 2024 · Synced Oct 4, 2026, 7:18 AM EDT
Completed Not applicable Interventional

The Effects of Omega-3 Fatty Acids Supplementation on Endothelial Function and Inflammation

NCT01310270
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Pro-Omega, Omega 3 Fatty Acid
Dietary Supplement
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 4, 2026, 7:18 AM EDT
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

Docosahexaenoic Acid (DHA) Supplementation in Amblyopia

NCT03402789
View directory record Official record
Conditions
Amblyopia
Interventions
Docosahexaenoic Acid, Placebo Oral Tablet
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
3 Years to 17 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 9, 2024 · Synced Oct 4, 2026, 7:18 AM EDT
Withdrawn Not applicable Interventional

Docosahexaenoic Acid Supplementation of Women With Hypertension in Pregnancy to Improve Endothelial Health

NCT02137408
View directory record Official record
Conditions
Hypertension in Pregnancy
Interventions
Docosahexaenoic acid 200 mg, Docosahexaenoic acid 1000 mg
Dietary Supplement · Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Oct 4, 2026, 7:18 AM EDT
Completed Phase 3 Interventional Results available

Age-Related Eye Disease Study 2 (AREDS2)

NCT00345176
View directory record Official record
Conditions
Age-related Macular Degeneration, Cataract
Interventions
Lutein/zeaxanthin, DHA/EPA, Lutein/zeaxanthin and DHA/EPA
Dietary Supplement · Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years to 85 Years
Enrollment
4,203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
91
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 72 more
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Oct 4, 2026, 7:18 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

DHA Supplementation and Pregnancy Outcome

NCT00266825
View directory record Official record
Conditions
Pregnancy
Interventions
DHA, Placebo capsule
Drug · Other
Lead sponsor
Susan Carlson, PhD
Other
Eligibility
16 Years to 36 Years · Female only
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
2
States / cities
Kansas City, Kansas • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 4, 2026, 7:18 AM EDT
Not listed Phase 2 Interventional

A Randomized Trial of LOVAZA in Pediatric Sickle Cell Disease (SCD)

NCT01202812
View directory record Official record
Conditions
Sickle Cell Disease, HEMOGLOBIN SS, Hemoglobin S Beta-0 Thalassemia, Inflammation, Quality of Life
Interventions
Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA), Placebo Capsules
Dietary Supplement · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
10 Years to 19 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 25, 2010 · Synced Oct 4, 2026, 7:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Long-Chain Polyunsaturated Fatty Acid Supplementation on Toddler Cognition

NCT00982462
View directory record Official record
Conditions
Infant Development
Interventions
Docosahexaenoic acid (DHA) and arachidonic acid (ARA), Corn oil placebo
Dietary Supplement
Lead sponsor
Retina Foundation of the Southwest
Other
Eligibility
351 Days to 379 Days
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 4, 2026, 7:18 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Effects of Docosahexaenoic Acid (DHA) on Cognitive Function in Children 4 Years of Age

NCT00351624
View directory record Official record
Conditions
Healthy
Interventions
DHA, placebo
Behavioral
Lead sponsor
dsm-firmenich Switzerland AG
Industry
Eligibility
4 Years to 4 Years
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
10
States / cities
Los Angeles, California • Stockbridge, Georgia • DeKalb, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 4, 2026, 7:18 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Anxiety and Anorexia Nervosa in Adolescents

NCT01933243
View directory record Official record
Conditions
Anxiety, Anorexia Nervosa
Interventions
Fish oil, Placebo pill
Drug
Lead sponsor
Andrea Bonny
Other
Eligibility
12 Years to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Oct 4, 2026, 7:18 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation

NCT01208961
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
Epanova (4 g) and Lovaza (4 g), Lovaza (4 g) and Epanova (4 g)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 15, 2015 · Synced Oct 4, 2026, 7:18 AM EDT
Terminated Phase 3 Interventional Results available

Effects of Eicosapentaenoic Acid on Endothelial Function in Diabetic Subjects

NCT02422446
View directory record Official record
Conditions
Type 2 Diabetes, Coronary Artery Disease
Interventions
Icosapent ethyl
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
30 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2022 · Synced Oct 4, 2026, 7:18 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Personalized Approach

NCT02553915
View directory record Official record
Conditions
Major Depressive Disorder, Overweight, Inflammation
Interventions
Placebo, EPA 1 g/day, EPA 2 g/day, EPA 4 g/day
Other · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
2
States / cities
Atlanta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Oct 4, 2026, 7:18 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Efficacy of Diet on Quality of Life in Multiple Sclerosis

NCT05007483
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
BodyBio Balance Oil, Kirunal Fish Oil, BodyBio PC, Modified Paleolithic Elimination diet, Time Restricted Olive Oil Based (TROO) Ketogenic Diet, Usual diet with Dietary Guidelines for Americans Diet information
Dietary Supplement · Behavioral
Lead sponsor
Terry L. Wahls
Other
Eligibility
18 Years to 70 Years
Enrollment
162 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 4, 2026, 7:18 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Understanding Fish Consumption Habits During Pregnancy

NCT01178398
View directory record Official record
Conditions
Nutrition
Interventions
Not listed
Lead sponsor
Harvard Pilgrim Health Care
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 4, 2026, 7:18 AM EDT
Completed Phase 1 Interventional

Evaluation of DHA for the Treatment of PSC

NCT00325013
View directory record Official record
Conditions
Primary Sclerosing Cholangitis, Colitis
Interventions
Docosahexaenoic Acid (DHA)
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
2
States / cities
Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 11, 2015 · Synced Oct 4, 2026, 7:18 AM EDT
Completed Not applicable Interventional

The Triglyceride Lowering Effect of an Omega-3 Fat (DHA) in Addition to Statin Therapy for Patients With CAD or Diabetes

NCT00360217
View directory record Official record
Conditions
Hypertriglyceridemia (TG>200<500), Hyperlipidemia, Coronary Artery Disease, Coronary Risk Equivalent, Diabetes
Interventions
docosahexanoic acid (DHA)
Drug
Lead sponsor
Maine Center for Lipids and Cardiovascular Health
Other
Eligibility
21 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Scarborough, Maine
Source: ClinicalTrials.gov public record
Updated Nov 18, 2011 · Synced Oct 4, 2026, 7:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Placebo Controlled Double Masked Clinical Assessment Study of Essential Fatty Acid Supplement and Its Effect on Patients With Apparent Aqueous Deficient Dry Eye Syndrome

NCT00344721
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Omega-3 fatty acid supplement, Placebo
Dietary Supplement
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 4, 2026, 7:18 AM EDT